METHODS	Patients were randomized to receive 3-week cycles of either arm A : PS-341 1.5 mg/m ( 2 ) i.v. bolus ( over 3 -- 5 s ) on days 1 , 4 , 8 and 11 or arm B : PS-341 1.0 mg/m ( 2 ) ( same as arm A otherwise ) plus gemcitabine 1,000 mg/m ( 2 ) i.v. on days 1 and 8 .\